You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,113,000


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,113,000
Title:Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin\'s lymphomas.
Inventor(s): Grillo-Lopez; Antonio J. (South San Francisco, CA)
Assignee: Biogen Inc. (Cambridge, MA)
Application Number:15/225,594
Patent Claims:1. A method for treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m.sup.2 of rituximab during a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapeutic regimen, wherein the CHOP chemotherapy and rituximab are administered to the patient on Day 1 of each CHOP chemotherapy cycle.

2. The method of claim 1 wherein the method provides a beneficial synergistic effect in the patient.

3. The method of claim 1 wherein 375 mg/m.sup.2 of rituximab is administered to the patient once every 3 weeks.

4. A method for treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m.sup.2 of an anti-CD20 antibody during a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapeutic regimen, wherein the CHOP chemotherapy and the antibody are administered to the patient on Day 1 of each CHOP chemotherapy cycle, and wherein the antibody comprises a light chain variable region comprising the amino acid sequence in SEQ ID NO: 1 and a heavy chain variable region comprising the amino acid sequence in SEQ ID NO: 2, and comprises human gamma 1 heavy-chain and kappa light-chain constant region amino acid sequences.

5. The method of claim 4 wherein the method provides a beneficial synergistic effect in the patient.

6. The method of claim 4 wherein 375 mg/m.sup.2 of the antibody is administered to the patient once every 3 weeks.

7. A method for treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m.sup.2 of rituximab once every three weeks during cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, wherein the CHOP chemotherapy and rituximab are administered to the patient on Day 1 of each CHOP chemotherapy cycle.

8. The method of claim 7 wherein the method provides a beneficial synergistic effect in the patient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.